URL has been copied successfully!
Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound.
In a one-year trial of patients who weren’t receiving PAP therapy, a form of ventilation, those on Foundayo saw a reduction of 17.8 “events” per hour on the apnea-hypopnea index (AHI), a measure of the number of times breathing stops and becomes restricted while sleeping. That compares with a reduction of 4.5 events among those on placebo.
Additionally, 28% of treated patients achieved remission or mild disease, compared with 13% in the placebo group, according to data presented Monday at the annual meeting of the American Heart Association and published in JAMA.
Share this story:
